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ABSTRACT
Objective: To compare the frequency of fungal infection and mortality rates in patients with hematological malignity 
and receiving either flucanazole (FLU) or posaconazole (POS) prophylaxis.
Methods: This retrospective, observational study investigated fungal prophylaxis in patients with a high risk of inva-
sive fungal infections (IFIs) and diagnosed with hematological malignity at our hospital hematology clinic between 
01.01.2011 and 01.01.2013. FLU (n=70) was the prophylactic regimen between 2011 and 2012 which was replaced by 
POS (n=35) in the following period. The incidence and mortality rates of IFIs developing in the two periods were com-
pared.
Results: The incidence of IFI in patients administered FLU prophylaxis was 22/70 (31%), compared to 13/35 (37%) in the 
patients receiving POS. Incidence of invasive pulmonary aspergillosis (IPA) in the FLU group was 21/70 (31%), compared 
to 9/35 (26%) in the POS group. The mortality rate in the group receiving FLU prophylaxis was 17 (24%), compared 
to 4 (11%) in the POS group. The difference was attributed to causes other than fungal infection. Results of subgroup 
analysis performed for AML were similar to the general findings in terms of both incidences of fungal infection and of 
mortality levels. In multivariate analysis, mean duration of neutropenia was correlated with prophylaxis failure.
Conclusion: We conclude that both agents can be successfully used in fungal infection prophylaxis for patients at high 
risk for IFI. J Microbiol Infect Dis 2014;4(1): 1-6
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Hematojlojik malignitesi olan yüksek riskli hastalarda flukonazol ve posakonazol 
proflaksisinin karşılaştırılması
ÖZET
Amaç: Bu çalışmada hematolojik malignitesi olan ve flukonazol (FLU) veya posakonazol (POS) proflaksisi uygulanan 
hastalarda görülen fungal enfeksiyon sıklığı ve mortalite oranları karşılaşıldı. 
Yöntemler: Bu retrospektif, gözlemsel çalışmada 01 Ocak 2011-01 Ocak 2013 tarihleri arasında hastanemiz hematoloji 
kliniğinde hematolojik malignite tanısıyla izlenmekte olan hastalara verilen antifungal profilaksiler değerlendirildi. Birer 
yıllık 2 dönemin ilkinde, hastalara proflaktik olarak FLU, 2.dönemde ise POS uygulandı.  
Bulgular: FLU proflaksisi alan hastalarda görülen fungal enfeksiyon sıklığı 22/70 (31%) iken, POS alan hastalarda 13/35 
(37%) olduğu görüldü. İnvaziv pulmoner aspergilloz (İPA) görülme sıklığı FLU kolunda 21/70 (31%) bulunurken, POS 
kolunda bu oran 9/35 (%26) bulundu. FLU proflaksisi alan gruptan 17 hasta öldü (%24), POS alan gruptan ise 4 (%11) 
hasta öldü. Bu farkın fungal enfeksiyon dışı nedenlerden kaynaklandığı düşünüldü. AML için yapılan subgrup analizinde 
fungal enfeksiyon sıklığı ve mortalite oranları bakımından sonuçlar, genel sonuçlarla benzerdi. Çoklu varyasyon analizin-
de hastalardaki ortalama nötropeni süresinin uzunluğuyla fungal proflaksi başarısızlığı arasında ilişki bulundu.
Sonuç: Her iki ajanın da yüksek riskli hastalardaki fungal enfeksiyon proflaksisinde başarıyla kullanılabileceği sonucuna 
varıldı.
Anahtar kelimeler: Fungal proflaksi, invaziv fungal enfeksiyonlar, mortalite.Kaya S, et al. Fungal prophylaxis in high risk patients 2
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INTRODUCTION
Patients receiving intense/high-dose chemothera-
py for acute leukemia and with deep neutropenia 
lasting more than one week are at greater risk of 
developing invasive fungal infections (IFIs).1,2 The 
prophylactic approach is therefore important, par-
ticularly for patients identified as being at high-risk. 
Antifungal drugs are now available for prophy-
laxis, which was a controversial issue until recently. 
However, there is as yet no consensus on which 
agent  should  be  preferred  in  prophylaxis.3-6 This 
study investigated the effectiveness of flucanazole 
(FLU) and posaconazole (POS) applied as prophy-
lactic agents in high-risk patients with hematological 
malignity.
METHODS
This  retrospective,  observational  study  investi-
gated fungal prophylaxis in patients at high risk of 
IFI and diagnosed with hematological malignity at 
our hospital hematology clinic between 01.01.2011 
and 01.01.2013. Patients who had undergone bone 
marrow or solid organ transplantation were exclud-
ed from the study.
Tests such as blood cultures, pulmonary high 
resolution  computerized  tomography  (HRCT),  se-
rum galactomannan (GM) levels and histopatho-
logical analysis were used in diagnosing IFI, in ad-
dition to clinical evaluation. GM was investigated 
regularly, twice a week, in these patients, and the 
result was regarded as positive when >0.5 in two 
consecutive  specimens  and  >0.7  in  a  single  se-
rum specimen.7 Under the European Organization 
for the Treatment of Cancer/Mycoses Study Group 
(EORTC/MSG) guideline, cases are evaluated as 
possible, probable or proven.8 Possible pulmonary 
fungal disease (PFD) was defined as radiological 
findings  concordant  with  PFD  without  microbio-
logical evidence and probable invasive pulmonary 
aspergillosis (IPA) was diagnosed based on radio-
logical evidence and GM positivity. Bronchoscopy 
could only be performed in three of these patients. 
No aspergillus growth was seen in any specimen, 
and no results histopathologically compatible with 
aspergillosis were obtained.
Our hospital’s hematology and infectious dis-
eases departments meet every six months to as-
sess  hematological  patients’  current  data  and  to 
determine the protocols to be applied in monitoring, 
prophylaxis and treatment. Under this approach, 
considering one-year patient data between January 
1st 2011 and January 1st 2012 and in the light of the 
current literature, we decided that POS should be 
used as of January 1st 2012 in the prophylaxis of 
patients at high risk for IFI. Therefore, in this study, 
patients at high risk for IFI and monitored between 
January 1st 2011 and January 1st 2012 were given 
400 mg/d FLU (400 mg/d) by the oral route (Period 
1),  while  between  January  1st  2012  and  January 
1st 2013, similar patients were administered POS 
(3x200 mg/d) prophylaxis by the oral route (Period 
2).  Seventy  patients  were  given  FLU  prophylaxis 
in the first period, and 35 patients were given POS 
prophylaxis in the second. Patients given prophy-
laxis had no fungal infection prior to prophylaxis. 
On the basis of up-to-date guideline recommenda-
tions, high risk for IFI was defined as deep neutro-
penia (<100/mm3) lasting more than 1 week. Fungal 
prophylaxis was initiated for patients expected to 
remain in deep neutropenia for more than 1 week 
and due to receipt of induction chemotherapy, at 
the stage when chemotherapy initiated. Prophy-
laxis was maintained until patients left the high risk 
group. Fungal prophylaxis was given to all patients 
during hospitalization, and these cases were moni-
tored up to the end of prophylaxis. Approval was re-
ceived from the Ministry of Health for off-label use 
of POS prophylaxis in patients with disorders other 
than acute myelocytic leukemia (AML) and myelo-
dysplastic  syndrome  (MDS).  The  incidence  and 
mortality rates of IFIs developing in patients in both 
periods were then compared. Since the prophylac-
tic efficacy of POS for malignities other than AML 
is not well known, our AML patient group was also 
assessed using subgroup analysis.
During the first period there was a construction 
in stem cell transplantation ward which is close to 
the hematology ward where patients receive high 
dose chemotherapy for several hematologic malig-
nancies. In the second period when POS is used 
there was no construction. Apart from POS prophy-
laxis, no change was made in the second period 
compared to the first in terms of preventing fungal 
infections.
Failure of antifungal prophylaxis was interpret-
ed as the development of IPA and microbiologically 
documented fungal infection in cases despite pro-
phylaxis and/or the commencement of empiric an-
tifungal therapy while prophylaxis was continuing.
Statistical analysis
The study data were transferred to SPSS 13.0 and 
analyzed  using  the  chi-square  test.  Significance 
was set at p<0.05. Variables thought of as a risk 
factor for failure of antifungal prophylaxis was ana-
lyzed with multivariate logistic regression analysis. Kaya S, et al. Fungal prophylaxis in high risk patients 3
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These variables were mean duration of neutrope-
nia, status of underlying disease, type of antifungal 
prophylaxis, nausea and vomiting at antifungal pro-
phylaxis.
RESULTS
One hundred and five patients who received anti-
fungal prophylaxis were evaluated, 67 (64%) male 
and 38 (36%) female. Mean age was 44.5±8 years 
(between 17 and 65 years). In terms of underlying 
diseases, 50 (48%) consisted of acute myeloid leu-
kemia (AML), 35 (33%) acute lymphocytic leukemia 
(ALL),  11  (10%)  Hodgkin  and  non-Hodgkin  lym-
phoma, and 9 (9%) multiple myeloma. All the pa-
tients given antifungal prophylaxis had received re-
mission-induction chemotherapy. Mean duration of 
neutropenia in both groups was above 2 weeks, and 
the duration of neutropenia were similar (18.4±3.0 
and 19.5±2.0 days, respectively, p=0.463).
FLU  prophylaxis  was  given  to  70  patients  in 
2011.  Rhinocerebral mucormycosis was deter-
mined in one of these and invasive pulmonary as-
pergillosis in 13 cases as probable infection. POS 
prophylaxis was given to 35 patients in 2012. Can-
dida krusei, Candida norvegensis and Trichosporon 
beigelii  strain  were  detected  in  blood  cultures  of 
three cases. Probable IPA developed in eight pa-
tients. The prevalence of fungal infection in all pa-
tients receiving FLU prophylaxis was 22/70 (31%), 
compared to 13/35 (37%) in patients receiving POS 
(p=0.827). A similar situation applies in terms of IPA. 
The incidence of IPA in the FLU group was 21/70 
(31%), compared to 9/35 (26%) in the POS group 
(p=0.705). The difference was not statistically sig-
nificant.  In  terms  of  levels  of  commencement  of 
empiric antifungal treatment, these were 15 (21%) 
in the FLU group and 7 (20%) in the POS group 
(p=0.932). Antifungal prophylaxis failed in 37 (53%) 
cases in the FLU group and 20 (57%) in the POS 
group (p=0.845). When subgroup analysis was per-
formed for AML, IFIs were seen in 12/33 (36%) of 
patients in the FLU group and 6/17 (35%) in the 
POS group (p=0.650). Incidence of IPA in the FLU 
group was 12/33 (36%), and 5/17 (29%) in the POS 
group  (p=0.813).  Antifungal  prophylaxis  failed  in 
20 (60%) cases in the FLU group and in 10 (59%) 
in  the  POS  group  (p=0.854).  Demographic  char-
acteristics, fungal infections and prognoses of the 
patients  receiving  FLU  and  POS  prophylaxis  are 
shown in Tables 1 and 2.
Variables FLU prophylaxis,
(n=70)
POS prophylaxis
(n=35)
P value
Age, Mean±SD (min-max) 44.6±8.5 (17-65) 44.4±7.5 (18-60) 0.452
Sex (M) 45 (64%) 22 (63%) 0.942
Underlying diseases
   Acute myeloid leukemia (AML)
   Acute lymphocytic leukemia (ALL)
   Hodgkin/non-Hodgkin lymphoma
   Multiple myeloma (MM)
33 (47%)
23 (33%)
8 (11%)
6 (9%)
17 (48.5%)
12 (34%)
3 (9%)
3 (8.5%)
0.944
0.941
0.916
0.646
Status of underlying diseases
   New diagnosis
   Relapse
   Refractory
10 (14%)
35 (50%)
25 (36%)
3 (8.5%)
17 (48.5%)
15(43%)
0.944
0.944
0.618
Mean duration of neutropenia (day)±SD 18.4±3.0 19.5±2.0 0.463
Fungal infection agents
   Candida albicans
   Non-albicans Candida
   Rhinocerebral mucormycosis
   Trichosporon beigelii
   Possible pulmonary fungal disease+IPA
   Total
0
0
1 (7%)
0
21 (31%)
22 (31%)
1 (8%)
2 (17%)
0
1 (8%)
9 (26%)
13 (37%)
0.705
0.827
Antifungal treatment starting empirically 15 (%21) 7 (20%) 0.932
Failure of antifungal prophylaxis 37 (53%) 20 (57%) 0.835
Ex 17 (24%) 4 (8%) 0.195
FLU= Flucanazole, POS= Posaconazole, IFI= Invasive fungal infection, IPA= Invasive pulmonary 
aspergillosis, SD= Standart deviation.
Table 1.  Patients’ 
demographic char-
acteristics, fun-
gal infections and 
prognoses.Kaya S, et al. Fungal prophylaxis in high risk patients 4
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Variables
FLU prophylaxis
(n=33)
POS prophylaxis
(n=17) P value
Age, Mean±SD (min-max.) 43±7.0 (17-65) 43±8.0 (18-60) 0.552
Sex (Male) 23 (70%) 11 (65%) 0.937
Status of underlying diseases
   New diagnosis
   Relapse
   Refractory
3 (9%)
18 (55%)
12 (36%)
2 (11%)
9 (53%)
7(36%)
0.944
0.812
0.928
Chemotherapy protocol
   Remission-induction 33 (100%) 17 (100%) 0.944
Fungal infection agents
   Non-albicans Candida
   IPA
   Total
0
12 (36%)
12 (36%)
1 (14%)
5 (29%)
6 (35%)
0.813
0.650
Empiric antifungal treatment 8 (24%) 4 (23.5%) 0.621
Failure of antifungal prophylaxis 20 (60%) 10 (59%) 0.854
Ex 8 (24%) 2 (12%) 0.461
FLU= Flucanazole, POS= Posaconazole, IFI= Invasive fungal infection, IPA= Invasive 
pulmonary aspergillosis, SD= Standart deviation.
Table 2.  AML  patients’ 
demographic characteris-
tics fungal infections and 
prognoses
Risk factors
Odds ratio
(OR)
95% Confidence
Interval P value
Mean duration of neutropenia 5.5 3.0-9.5 0.01
Status of underlying disease 1.2 0.8-2.9 0.06
Type of antifungal prophylaxis 1.0 0.7-1.4 0.08
Nausea and vomiting on antifungal prophylaxis 1.1 0.7-1.6 0.07
Table 3. Multivariate 
regression analysis 
of failure of antifun-
gal prophylaxis in 
patients
Risk factors Odds ratio
(OR)
95% Confidence
Interval P value
Mean duration of neutropenia 5.7 3.0-9.8 0.01
Status of underlying disease 1.1 1.4-20 0.08
Type of antifungal prophylaxis  1.0 0.8-1.2 0.09
Nausea and vomiting on antifungal prophylaxis 1.2 0.9-2.6 0.07
Table 4. Multivariate 
regression analysis 
of failure of antifun-
gal prophylaxis in 
AML subgroup
Multivariate logistic regression analysis was 
used to investigate the factors related to antifungal 
prophylaxis failure. Mean duration of neutropenia, 
status of underlying disease, type of antifungal pro-
phylaxis, nausea and vomiting and antifungal pro-
phylaxis were included in two separate analyses. 
The first evaluation was done for all patients receiv-
ing antifungal prophylaxis, and then AML subgroup 
of patients (Table 3 and 4). Only mean duration of 
neutropenia was determined to be correlated with 
breakthrough IFIs (OR 5.5, 95%CI 3.0-9.5, p=0.01, 
OR 5.7, 95%CI 3.0-9.8, p=0.01, respectively).
The most frequent side effects associated with 
both antifungals were those involving the gastroin-
testinal system, mainly taking the form of nausea-
vomiting. Rate of nausea and vomiting were higher 
in  the  POS  patients  compared  to  those  receiv-
ing FLU, in 5% and 15% of patients, respectively 
(p=0.267).
Crude mortality (death due to any reason until 
resolution of neutropenia) in the FLU prophylaxis 
group was 17 (24%), compared to 4 (8%) in the 
group receiving POS (p=0.195). For AML patients, 
these levels were 8 (24%) in the FLU group and 2 
(12%) in the POS group (p=0.207).Kaya S, et al. Fungal prophylaxis in high risk patients 5
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DISCUSSION
Since IFI causes high mortality, patients at high risk 
of these developing infections should be adminis-
tered prophylaxis. Additionally, IFIs lead to a delay 
in  the  chemotherapy  procedure  to  be  applied  to 
such patients and complicate the treatment of the 
underlying disease.3 Patients developing IFI have 
longer terms of hospitalization, and higher mortal-
ity rates and hospital costs compared to patients 
without IFI.3 However, broad, controlled studies are 
needed in order to be able to recommend routine 
antifungal prophylaxis in these patients. 
Opinions  differ  regarding  which  prophylactic 
agent  should  be  given,  although  the  ideal  agent 
should have a broad spectrum, be well tolerated 
and come in oral and parenteral forms. In that con-
text,  amphotericin  B,  FLU,  voriconazole,  itracon-
azole (ITZ), POS, caspofungin and micafungin are 
antifungals with differing mechanisms that can be 
employed in prophylaxis.9-14
One large study involving 603 MDS and AML 
patients with remission induction compared the ef-
fectiveness of POS and FLU/ITZ in these long-term 
neutropenic  subjects.  Proven/probable  IFI  was 
significantly lower in the POS group. Survival was 
also  significantly  higher  in  the  POS  group.  Side-
effects involving the gastrointestinal system were 
the most common effects in both groups.15 In one 
study performed in China, the prophylactic efficacy 
of FLU and POS was compared in AML and MDS 
patients.16  One  hundred  twenty-three  patients  re-
ceived  FLU  in  that  study,  and  129  POS.  Clinical 
failure and incidence of IPA were significantly low-
er in the POS group compared to the FLU group, 
and time of commencement of antifungal therapy 
was significantly longer. The drug side-effects were 
at similar levels in the two groups, and the study 
concluded by emphasizing that POS was a good 
prophylactic option in patients at high risk for IFIs. 
In another study, Bertz et al.17 compared FLU and 
POS in prophylaxis in patients at high risk for IFI.7 
No mortality was seen in that study, and no signifi-
cant difference was determined between the groups 
in terms of commencement of antifungal therapy.
In our retrospective analysis, the prevalence of 
fungal infection and rates of commencement of em-
piric antifungal therapy were lower in the FLU group 
compared to the POS group. This might be partially 
related to poor absorption of POS from gastroin-
testinal system in case of nausea-vomiting. In ad-
dition, however, no significant relation was seen at 
multivariate  logistic  regression  analysis  between 
gastrointestinal  complaints  caused  by  antifungal 
drugs  and  failure  seen  in  fungal  prophylaxis.  Of 
the parameters investigated in this analysis, only 
mean duration of neutropenia was correlated with 
prophylaxis failure. The incidence of IPA in the FLU 
group in our study was higher than that in the POS 
group, though the difference was not significant. We 
thought that construction work carried out in the first 
period might have been a factor in IPA developing in 
the study period. Although there was no statistically 
significant difference between mortality rates in the 
two prophylaxis groups in our study, it was higher in 
the FLU group. Since there were a large number of 
treatment-refractory patients in the FLU group, we 
thought that the poor prognostic course associated 
with the primary disease might be attributed to this. 
Results  of  subgroup  analysis  performed  for AML 
were similar to the general findings in terms of both 
incidences of fungal infection and mortality levels. 
Mean duration of neutropenia was found to be cor-
related with prophylaxis failure also in this group.
In summary, IFI and crude morality rates were 
similar in the two groups. We conclude that both of 
FLU and POS can be successfully used in fungal 
infection prophylaxis for patients at high risk for IFIs. 
We believe that our study will shed light on a pro-
spective study we are planning for the next stage 
involving a wider patient series under more stan-
dardized conditions.
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